The United Laboratories International Holdings (HK:3933) has released an update.
The United Laboratories International Holdings has announced that its Ceftazidime for Injection has passed the quality and efficacy consistency evaluation, strengthening its position in the anti-infective market. This product, a third-generation cephalosporin antibiotic, is used for a variety of infections and is included in China’s National Essential Drug List. The approval supports the company’s ongoing commitment to developing innovative healthcare solutions.
For further insights into HK:3933 stock, check out TipRanks’ Stock Analysis page.
